Bumetanide for autism: more eye contact, less amygdala activation
View/ Open
Author
Åsberg Johnels, Jakob
Lassalle, Amandine
Zürcher, Nicole R.
Hippolyte, Loyse
Gillberg, Christopher
Lemonnier, Eric
Ben-Ari, Yehezkel
Published Version
https://doi.org/10.1038/s41598-018-21958-xMetadata
Show full item recordCitation
Hadjikhani, Nouchine, Jakob Åsberg Johnels, Amandine Lassalle, Nicole R. Zürcher, Loyse Hippolyte, Christopher Gillberg, Eric Lemonnier, and Yehezkel Ben-Ari. 2018. “Bumetanide for autism: more eye contact, less amygdala activation.” Scientific Reports 8 (1): 3602. doi:10.1038/s41598-018-21958-x. http://dx.doi.org/10.1038/s41598-018-21958-x.Abstract
We recently showed that constraining eye contact leads to exaggerated increase of amygdala activation in autism. Here, in a proof of concept pilot study, we demonstrate that administration of bumetanide (a NKCC1 chloride importer antagonist that restores GABAergic inhibition) normalizes the level of amygdala activation during constrained eye contact with dynamic emotional face stimuli in autism. In addition, eye-tracking data reveal that bumetanide administration increases the time spent in spontaneous eye gaze during in a free-viewing mode of the same face stimuli. In keeping with clinical trials, our data support the Excitatory/Inhibitory dysfunction hypothesis in autism, and indicate that bumetanide may improve specific aspects of social processing in autism. Future double-blind placebo controlled studies with larger cohorts of participants will help clarify the mechanisms of bumetanide action in autism.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827728/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981982
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)